Attached files
| file | filename |
|---|---|
| EX-32.1 - HARROW HEALTH, INC. | ex32-1.htm |
| EX-31.2 - HARROW HEALTH, INC. | ex31-2.htm |
| EX-31.1 - HARROW HEALTH, INC. | ex31-1.htm |
| EX-23.1 - HARROW HEALTH, INC. | ex23-1.htm |
| EX-21.1 - HARROW HEALTH, INC. | ex21-1.htm |
| EX-10.55 - HARROW HEALTH, INC. | ex10-55.htm |
| EX-10.54 - HARROW HEALTH, INC. | ex10-54.htm |
| EX-10.53 - HARROW HEALTH, INC. | ex10-53.htm |
| 10-K - HARROW HEALTH, INC. | form10-k.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Imprimis Pharmaceuticals, Inc. (the “Company”) for the period ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Andrew R. Boll, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: March 8, 2018 | |
/s/ Andrew R. Boll |
|
| Andrew R. Boll | |
| Chief Financial Officer |
This certification accompanies this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.